What This Bill Does · Plain English
Summary · Congress.gov
Women’s Heart Health Expansion Act of 2026 This bill reauthorizes through FY2031 and expands a grant program that supports preventive health services (e.g., screenings, referrals) regarding women’s cardiovascular health. This program is known as the Well-Integrated Screening and Evaluation of Women Across the Nation (WISEWOMAN) program, which is administered by the Centers for Disease Control and Prevention (CDC). Under current law, only three states may receive a WISEWOMAN grant, and health care providers and recipients of services must participate in the CDC’s National Breast and Cervical Cancer Early Detection Program in order to qualify under the WISEWOMAN program. The bill revises the WISEWOMAN program by (1) removing the three-state limitation, (2) allowing providers to participate even if not providing services under the other CDC program (as determined by the CDC), and (3) allowing participation of high-risk women who are not eligible under the other CDC program (based on CDC criteria). Additionally, the bill requires the Government Accountability Office to report to Congress on the work of the WISEWOMAN program.
Carveouts & Earmarks · 1 line items · $250M tagged
Specific dollar amounts in this bill that flow to identifiable companies or programs — the actual cash trail.
$250M
Sec. 2 (amending Sec. 1509(d))
"To carry out this section, there is authorized to be appropriated $250,000,000 for the period of fiscal years 2027 through 2031."
→ Secretary, acting through the Director of the Centers for Disease Control and Prevention
Action Timeline
2026-03-19
Committee on Health, Education, Labor, and Pensions. Hearings held.
2026-02-26
Introduced in Senate
2026-02-26
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Frequently Asked Questions
Did S.3944 pass?
S.3944 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
What does S.3944 do?
Women’s Heart Health Expansion Act of 2026 This bill reauthorizes through FY2031 and expands a grant program that supports preventive health services (e.g., screenings, referrals) regarding women’s cardiovascular health. This program is known as the Well-Integrated Screening and Evaluation of Women Across the Nation (WISEWOMAN) program, which is administered by the Centers for Disease Control and Prevention (CDC). Under current law, only three states may receive a WISEWOMAN grant, and health care providers and recipients of services must participate in the CDC’s National Breast and Cervical Ca…
Who sponsored S.3944?
S.3944 was sponsored by Angela D. Alsobrooks (D-Maryland).
How much money does S.3944 spend?
S.3944 contains $250M in identified line-item carveouts to specific programs and companies, across 1 earmarks.
Full Bill Text
119 S3944 IS: Women’s Heart Health Expansion Act of 2026 U.S. Senate 2026-02-26 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. II 119th CONGRESS 2d Session S. 3944 IN THE SENATE OF THE UNITED STATES February 26, 2026 Ms. Alsobrooks (for herself and Mrs. Britt ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To amend the Public Health Service Act to reauthorize the WISEWOMAN program. 1. Short title This Act may be cited as the Women’s Heart Health Expansion Act of 2026 . 2. Reauthorization of WISEWOMAN program Section 1509 of the Public Health Service Act ( 42 U.S.C. 300n–4a ) is amended to read as follows: 1509. Supplemental grants for additional preventive health services (a) Screening and referral projects The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may award supplemental grants to recipients of grants under section 1501 to carry out projects for the purposes of— (1) providing preventive health services in addition to the services authorized in such section, including— (A) screenings regarding blood pressure, cholesterol, obesity, and other relevant risk factors; and (B) evidence-based health education offered by a qualified provider to improve a measurable health outcome, such as blood pressure, cholesterol, diabetes, or obesity; (2) providing appropriate referrals for medical treatment of women receiving services pursuant to paragraph (1) and ensuring, to the extent practicable, the provision of appropriate follow-up services; and (3) evaluating activities conducted under paragraphs (1) and (2) through appropriate surveillance or program-monitoring activities and reporting to the Secretary on such activities. (b) Eligibility for services Women eligible for services pursuant to a grant under subsection (a) shall include— (1) women eligible for services pursuant to a grant made under section 1501; and (2) other women who are high-risk and meet such eligibility criteria as the Secretary may specify. (c) Authorized providers Health services provided pursuant to a grant under subsection (a) shall be provided by— (1) an entity screening women for breast and cervical cancer pursuant to a grant under section 1501; or (2) other health care entities, as the Secretary determines. (d) Funding To carry out this section, there is authorized to be appropriated $250,000,000 for the period of fiscal years 2027 through 2031. . 3. GAO study Not later than September 30, 2027, the Comptroller General of the United States shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on the work of the Well-Integrated Screening and Evaluation for Women Across the Nation Program, including— (1) an estimate of the number of individuals eligible for services provided under such program; (2) a summary of trends in the number of individuals served through such program; (3) an assessment of any factors that may be driving the trends identified under paragraph (2), including any barriers to accessing cardiovascular health screenings provided by such program; and (4) an analysis of the cost-effectiveness of such program with respect to patient outcomes, such as blood pressure, cholesterol, diabetes, or obesity.
Loading intelligence layer…